News & Updates

The US Food and Drug Administration (FDA) has approved the first oral medication for postpartum depression in adults, giving clinicians a new therapeutic option for this debilitating condition.

Treatment with oral Janus kinase (JAK) inhibitors or jakinibs appeared well tolerated in patients with atopic dermatitis  (AD) as shown in an Asian retrospective cohort study.

Treatment with pitavastatin is associated with a significantly lower risk of cardiovascular (CV) events in people living with human immunodeficiency virus (HIV) as shown in the final analysis of the double-blind, placebo-controlled REPRIEVE trial presented at IAS 2023.

Treatment with nirmatrelvir plus ritonavir appears to reduce the incidence of hospitalization in a highly vaccinated population of high-risk COVID-19 patients in Malaysia, as shown in a study.

Misoprostol, a prostaglandin E1 analogue used to prevent nonsteroidal anti-inflammatory drug (NSAID)-related gastrointestinal disorders, appears effective in preventing kidney injury associated with chronic NSAID use, but the quality of evidence is very low, results of a recent study have shown.

Maintenance therapy with niraparib significantly extends progression-free survival (PFS) compared with placebo in patients with newly diagnosed advanced ovarian cancer who responded to treatment with first-line platinum-based chemotherapy, according to the PRIME* trial.